OKYO Pharma Plans To Accelerate Clinical Development Of urcosimod To Treat NCP Through Data Analysis Following Early Closure Of Phase 2 Trial

• Urcosimod phase 2 trial treating Neuropathic Corneal Pain ("NCP") patients was initiated in October 2024 and designed as a double-masked, randomized, 12-week placebo-controlled trial.
• OKYO Pharma plans to analyze the efficacy data from the 17 patients who have now completed the Phase 2 trial.
• OKYO Pharma plans for a meeting with FDA following evaluation of clinical data.

LONDON and NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an ocular condition associated with chronic and often severe pain but without an FDA-approved therapy, announces plans to accelerate the clinical development of urcosimod to treat NCP through the analysis of its data following the early closure of its Phase 2 trial.